DOP2022000234A - Compuestos útiles para inhibir la quinasa ret - Google Patents

Compuestos útiles para inhibir la quinasa ret

Info

Publication number
DOP2022000234A
DOP2022000234A DO2022000234A DO2022000234A DOP2022000234A DO P2022000234 A DOP2022000234 A DO P2022000234A DO 2022000234 A DO2022000234 A DO 2022000234A DO 2022000234 A DO2022000234 A DO 2022000234A DO P2022000234 A DOP2022000234 A DO P2022000234A
Authority
DO
Dominican Republic
Prior art keywords
compounds useful
ret kinase
ret
inhibiting ret
inhibiting
Prior art date
Application number
DO2022000234A
Other languages
English (en)
Inventor
L Mckenney Megan
R Kolakowski Gabrielle
D Anderson Erin
W Andrews Steven
R Condroski Kevin
C Irvin Thomas
Kumar Manoj
A Mcfaddin Elizabeth
J Munchhof Michael
B Welch Michael
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2022000234A publication Critical patent/DOP2022000234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

En la presente se proporcionan inhibidores de la quinasa RET de acuerdo con la fórmula: sales aceptables desde el punto de vista farmacéutico de estos, composiciones farmacéuticas de estos y métodos para su uso en el tratamiento de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidas enfermedades y trastornos asociados a RET. A, R1, n, X1, X2, X3, X4, y R2 tienen los significados dados en la memoria descriptiva.
DO2022000234A 2020-04-27 2022-10-27 Compuestos útiles para inhibir la quinasa ret DOP2022000234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063015933P 2020-04-27 2020-04-27
PCT/US2021/028836 WO2021222017A1 (en) 2020-04-27 2021-04-23 Compounds useful for inhibiting ret kinase

Publications (1)

Publication Number Publication Date
DOP2022000234A true DOP2022000234A (es) 2022-11-30

Family

ID=75914595

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000234A DOP2022000234A (es) 2020-04-27 2022-10-27 Compuestos útiles para inhibir la quinasa ret

Country Status (18)

Country Link
US (2) US11613533B2 (es)
EP (1) EP4143184A1 (es)
JP (1) JP7441972B2 (es)
KR (1) KR20230005301A (es)
CN (1) CN115667253A (es)
AR (1) AR121914A1 (es)
AU (1) AU2021263541B2 (es)
BR (1) BR112022021735A2 (es)
CA (1) CA3177080A1 (es)
CL (1) CL2022003000A1 (es)
CO (1) CO2022016013A2 (es)
DO (1) DOP2022000234A (es)
EC (1) ECSP22083926A (es)
IL (1) IL297551B2 (es)
MX (1) MX2022013482A (es)
PE (1) PE20230780A1 (es)
TW (1) TWI777509B (es)
WO (1) WO2021222017A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3197032A1 (en) 2020-11-06 2022-05-12 Eli Lilly And Company Pyrazole derivatives as ret kinase inhibitors
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
UA115264C2 (uk) * 2013-03-15 2017-10-10 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Піридинові похідні як інгібітори реаранжованої у процесі трансфекції (ret) кінази
WO2017145050A1 (en) * 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
US10183928B2 (en) * 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
CA3049136C (en) * 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2020035065A1 (zh) * 2018-08-17 2020-02-20 南京明德新药研发有限公司 作为ret抑制剂的吡唑衍生物

Also Published As

Publication number Publication date
AU2021263541B2 (en) 2024-03-07
US11964968B2 (en) 2024-04-23
US20230312544A1 (en) 2023-10-05
BR112022021735A2 (pt) 2022-12-06
TW202206428A (zh) 2022-02-16
PE20230780A1 (es) 2023-05-09
AU2021263541A1 (en) 2022-11-24
WO2021222017A1 (en) 2021-11-04
US20210363140A1 (en) 2021-11-25
AR121914A1 (es) 2022-07-20
IL297551B1 (en) 2024-02-01
IL297551A (en) 2022-12-01
MX2022013482A (es) 2022-11-16
US11613533B2 (en) 2023-03-28
JP2023523315A (ja) 2023-06-02
CN115667253A (zh) 2023-01-31
CO2022016013A2 (es) 2022-11-18
EP4143184A1 (en) 2023-03-08
KR20230005301A (ko) 2023-01-09
CA3177080A1 (en) 2021-11-04
ECSP22083926A (es) 2022-11-30
CL2022003000A1 (es) 2023-06-23
IL297551B2 (en) 2024-06-01
JP7441972B2 (ja) 2024-03-01
TWI777509B (zh) 2022-09-11

Similar Documents

Publication Publication Date Title
CO2022016013A2 (es) Compuestos útiles para inhibir la quinasa ret
DOP2019000091A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
DOP2019000090A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CL2023001738A1 (es) Inhibidores de prmt5
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
UY31679A1 (es) Inhibidores de cinasa pim y metodos para su uso
DOP2009000159A (es) Inhibidores de la poli(adp-ribosa) polimerasa
CO2019007888A2 (es) Inhibidores selectivos de jak1
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
AR063098A1 (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina
CL2022002695A1 (es) Inhibidores de rip1k
DOP2009000200A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
CR11208A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
AR085308A1 (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
CL2022003812A1 (es) Inhibidores de rip1k
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CO2023012903A2 (es) Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2)
AR127561A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
UY38133A (es) Nuevos inhibidores de cdk8/19
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
AR128426A1 (es) Compuestos heterocíclicos y métodos de uso